Machine Learning Promises to Revolutionize Gene Delivery. Researchers Have Already Made Strides.
Gene therapy is enormously complicated, inefficient and slow. Early tests of a newly developed machine learning model show how much faster, and more efficient, it might be.
The field of gene therapy has huge potential for curing genetic diseases. But transportation is a challenge.
To safely and effectively package and deliver new genes to specific cells, where they take over the role of faulty genes that cause disease, scientists most often engineer adeno-associated viruses to be gene-delivery vehicles. It is a painstaking process. But what if machine learning could provide a high-speed assist?
In study findings published earlier this month in Nature Communications, researchers at the Broad Institute of MIT and Harvard describe a machine-learning approach they developed. It helps engineer the protein shells of adeno-associated viruses (AAV), called capsids, to have multiple desirable traits, such as delivering therapy to one specific organ but not others, or to work in multiple species. Existing methods only look for capsids that have one trait at a time.
They then used their new tool, called Fit4Function, to design capsids for a type of adeno-associated virus called AAV9, which is frequently used as a vector , that more efficiently targeted the liver and could be easily manufactured. Roughly 90% of the capsids predicted by their machine learning models successfully delivered their cargo and met five other criteria.
What’s more, their machine learning (ML) model correctly predicted the behavior of the proteins in macaque monkeys – even though it was trained only on mouse and human cell data.
Benjamin E. Deverman, Ph.D.
First author Fatma-Elzahraa Eid, Ph.D., a senior machine learning scientist, and nearly all members of the team, are affiliated with the lab of institute scientist Benjamin E. Deverman, Ph.D., director of vector engineering at the Stanley Center for Psychiatric Research at the Broad Institute of MIT and Harvard, and the study’s corresponding author.
They’re looking ahead.
“The Fit4Function strategy ultimately makes it possible to predict cross-species traits of peptide-modified AAV capsids and is a critical step toward assembling an ML [machine learning] atlas that predicts AAV capsid performance across dozens of traits,” the authors wrote.
Patients Express Concerns Over Costs, Risks of Gene Therapies for Sickle Cell Disease
December 12th 2024Research at the annual meeting of the American Society of Hematology evaluated patient and caregiver perspectives on gene therapies for sickle cell disease, which offer great potential but have had slow uptake.
Read More
